{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:10:42Z","timestamp":1792127442944,"version":"4.4.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Eosinophilic asthma is a phenotype of asthma characterized by the persistence of eosinophils in the airways. IL-5 is involved in the activation and survival of eosinophils.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the effect of the antibody to IL-5, reslizumab, in patients with eosinophilic asthma that is poorly controlled with high-dose inhaled corticosteroid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomly assigned to receive infusions of reslizumab at 3.0 mg\/kg (n = 53) or placebo (n = 53) at baseline and at Weeks 4, 8, and 12, with stratification by baseline Asthma Control Questionnaire (ACQ) score less than or equal to 2 or greater than 2. The primary efficacy measure was the difference between the reslizumab and placebo groups in the change in ACQ score from baseline to end of therapy (Week 15 or early withdrawal).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Mean changes from baseline to end of therapy in ACQ score were \u20130.7 in the reslizumab group and \u20130.3 in the placebo group (P = 0.054) and in FEV1 were 0.18 and \u20130.08 L, respectively (P = 0.002). In those patients with nasal polyps, the changes in ACQ score were \u20131.0 and \u20130.1, respectively (P = 0.012). Median percentage reductions from baseline in sputum eosinophils were 95.4 and 38.7%, respectively (P = 0.007). Eight percent of patients in the reslizumab group and 19% of patients in the placebo group had an asthma exacerbation (P = 0.083). The most common adverse events with reslizumab were nasopharyngitis, fatigue, and pharyngolaryngeal pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients receiving reslizumab showed significantly greater reductions in sputum eosinophils, improvements in airway function, and a trend toward greater asthma control than those receiving placebo. Reslizumab was generally well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201103-0396oc","type":"journal-article","created":{"date-parts":[[2011,8,19]],"date-time":"2011-08-19T00:39:54Z","timestamp":1313714394000},"page":"1125-1132","source":"Crossref","is-referenced-by-count":630,"title":["Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-controlled Study"],"prefix":"10.1093","volume":"184","author":[{"given":"Mario","family":"Castro","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Mathur","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Hargreave","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Philippe","family":"Boulet","sequence":"additional","affiliation":[{"name":"Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Frazer, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Young","sequence":"additional","affiliation":[{"name":"United BioSource Corporation, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Jeffrey","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Frazer, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Henkel","sequence":"additional","affiliation":[{"name":"Cephalon, Inc., Frazer, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"2026032101202560000_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1183\/09031936.02.00232001","article-title":"Costs of asthma are correlated with severity: a 1-yr prospective study","volume":"19","author":"Godard","year":"2002","journal-title":"Eur Respir J"},{"key":"2026032101202560000_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00229.x","article-title":"Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma","volume":"11","author":"Chen","year":"2008","journal-title":"Value Health"},{"key":"2026032101202560000_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N Engl J Med"},{"key":"2026032101202560000_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1753465808092281","article-title":"Tissue remodeling and angiogenesis in asthma: the role of the eosinophil","volume":"2","author":"Nissim Ben Efraim","year":"2008","journal-title":"Ther Adv Respir Dis"},{"key":"2026032101202560000_bib5","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"2026032101202560000_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1183\/09031936.06.00137704","article-title":"Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations","volume":"27","author":"Jayaram","year":"2006","journal-title":"Eur Respir J"},{"key":"2026032101202560000_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.coi.2008.04.001","article-title":"IL-5 and eosinophilia","volume":"20","author":"Takatsu","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"2026032101202560000_bib8","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"2026032101202560000_bib9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti\u2013human interleukin-5 antibody, in severe persistent asthma: a pilot study","volume":"167","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101202560000_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032101202560000_bib11","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"2026032101202560000_bib12","first-page":"779","article-title":"Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity","volume":"49","author":"Egan","year":"1999","journal-title":"Arzneimittelforschung"},{"key":"2026032101202560000_bib13","article-title":"Reslizumab in the treatment of poorly controlled asthma in patients with eosinophilic airway inflammation","author":"Castro","year":"2010"},{"key":"2026032101202560000_bib14","doi-asserted-by":"crossref","first-page":"AB84","DOI":"10.1016\/j.jaci.2010.12.340","article-title":"Efficacy of reslizumab in patients with poorly controlled eosinophilic asthma: subgroup analysis of patients with nasal polyps [abstract]","volume":"127","author":"Mathur","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2026032101202560000_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and validation of a questionnaire to measure asthma control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"2026032101202560000_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.rmed.2004.10.008","article-title":"Measurement properties and interpretation of three shortened versions of the asthma control questionnaire","volume":"99","author":"Juniper","year":"2005","journal-title":"Respir Med"},{"key":"2026032101202560000_bib17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0091-6749(99)70118-1","article-title":"Eosinophilic airway inflammation in nasal polyposis","volume":"104","author":"Lamblin","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"2026032101202560000_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2273.2005.00969.x","article-title":"Activated eosinophils in nasal polyps: a comparison of asthmatic and non-asthmatic patients","volume":"30","author":"Bateman","year":"2005","journal-title":"Clin Otolaryngol"},{"key":"2026032101202560000_bib19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"2026032101202560000_bib20","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1378\/chest.11-0618","article-title":"Point: is measuring sputum eosinophils useful in the management of severe asthma. Yes","volume":"139","author":"Hargreave","journal-title":"Chest"},{"key":"2026032101202560000_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2222.2010.03637.x","article-title":"Are we closer to understanding the pathophysiology of chronic rhinosinusitis?","volume":"41","author":"Ling","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"2026032101202560000_bib22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11882-006-0026-3","article-title":"Pathogenesis of chronic rhinosinusitis","volume":"6","author":"Van Cauwenberge","year":"2006","journal-title":"Curr Allergy Asthma Rep"},{"key":"2026032101202560000_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.iac.2009.07.003","article-title":"Inflammation in chronic rhinosinusitis and nasal polyposis","volume":"29","author":"van Drunen","year":"2009","journal-title":"Immunol Allergy Clin North Am"},{"key":"2026032101202560000_bib24","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.158.8.3902","article-title":"Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia","volume":"158","author":"Simon","year":"1997","journal-title":"J Immunol"},{"key":"2026032101202560000_bib25","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti\u2013IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2026032101202560000_bib26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jaci.2004.12.1129","article-title":"Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids","volume":"115","author":"Deykin","year":"2005","journal-title":"J Allergy Clin Immunol"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/10\/1125\/67251409\/ajrccm_184_10_1125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/184\/10\/1125\/67251409\/ajrccm_184_10_1125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:20:35Z","timestamp":1774070435000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/184\/10\/1125\/8508363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2011,11,15]]},"published-print":{"date-parts":[[2011,11,15]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201103-0396oc","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13437011.14811136","asserted-by":"object"}]},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,11]]},"published":{"date-parts":[[2011,11]]}}}